BCR and B-cell chronic lymphocytic leukemia: In contrast to control IgH.TEμ mice, which showed ~35% (n = 7/20) VH11 usage, only 10% (n = 1/10) of IgH.TEμ.TD CLL expressed a VH11/Vκ14 BCR (Chi-square p = 0.09) (Figure 3B).